These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 16020962)

  • 1. Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and Paclitaxel as first-line treatment.
    Yang CH; Chen MC; Cheng AL; Hsu CH; Yeh KH; Yu YC; Whang-Peng J; Yang PC
    Oncology; 2005; 68(4-6):350-5. PubMed ID: 16020962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46).
    Johnson DH; Paul DM; Hande KR; DeVore R
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):42-6. PubMed ID: 9007120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer.
    Breathnach OS; Georgiadis MS; Schuler BS; Pizzella P; Llorens V; Kasturi V; Steinberg SM; O'Neil K; Takimoto CH; Johnson BE
    Clin Cancer Res; 2000 Jul; 6(7):2670-6. PubMed ID: 10914708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
    Socinski MA; Schell MJ; Bakri K; Peterman A; Lee JH; Unger P; Yates S; Hudgens S; Kies MS
    Cancer; 2002 Sep; 95(6):1265-73. PubMed ID: 12216094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
    Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.
    Langer CJ; Leighton J; McAleer C; Comis R; O'Dwyer P; Ozols R
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):64-9. PubMed ID: 7541156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
    Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
    Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
    Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel and carboplatin: a phase I study in advanced non-small cell lung cancer.
    Paccagnella A; Favaretto A; Oniga F; Ossana L
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):76-9. PubMed ID: 9007128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer.
    Mantovani G; Macciò A; Mulas C; Massa E; Madeddu C; Mura L; Contu P; Versace R
    Oncol Rep; 2002; 9(3):661-70. PubMed ID: 11956647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.
    Okamoto I; Moriyama E; Fujii S; Kishi H; Nomura M; Goto E; Kiyofuji C; Imamura F; Mori T; Matsumoto M
    Jpn J Clin Oncol; 2005 Apr; 35(4):188-94. PubMed ID: 15845567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel and carboplatin in inoperable non-small cell lung cancer.
    Kosmidis P; Mylonakis N; Fountzilas G; Samantas E; Athanasiadis A; Skarlos D
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):68-70. PubMed ID: 9007126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
    Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin.
    Rowinsky EK; Jiroutek M; Bonomi P; Johnson D; Baker SD
    Clin Cancer Res; 1999 Apr; 5(4):767-74. PubMed ID: 10213211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel (1-hour infusion) plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter phase II trial.
    Greco FA; Hainsworth JD
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-14-S12-17. PubMed ID: 9331113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
    Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
    Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel by either 1-hour or 24-hour infusion in combination with carboplatin in advanced non-small cell lung cancer: preliminary results comparing sequential phase II trials.
    DeVore RF; Jagasia M; Johnson DH
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-27-S12-29. PubMed ID: 9331116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Herbst RS; Hammond LA; Carbone DP; Tran HT; Holroyd KJ; Desai A; Williams JI; Bekele BN; Hait H; Allgood V; Solomon S; Schiller JH
    Clin Cancer Res; 2003 Sep; 9(11):4108-15. PubMed ID: 14519633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
    Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
    Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.